Clinical Trial Update: RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder [Phase 1, Phase 2]

View source ↗

Summary

This phase 1/2 trial evaluated intravesical gemcitabine in combination with RAD001 (everolimus) for BCG-refractory carcinoma in situ of the bladder. The study h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Carcinoma in Situ of the Bladder

Drugs mentioned

• Afinitor (everolimus)
• Gemzar (gemcitabine)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Bladder Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-03-13